Key result
Prior mediastinal radiotherapy in lymphoma survivors is linked to ~7-point lower LVEF on CMR vs. controls.
Why the study?
Long-term lymphoma survivors experience late radiotherapy and anthracycline toxicities causing premature cardiovascular morbidity and mortality, prompting the identification of subclinical cardiovascular disease markers using CMR.
Does cardiovascular magnetic resonance detect subclinical cardiovascular disease abnormalities in long-term survivors of Hodgkin and mediastinal non-Hodgkin lymphoma treated with mediastinal radiotherapy and/or anthracyclines compared with healthy control subjects?
Cross-Sectional (n=120)
No
Does cardiovascular magnetic resonance detect subclinical cardiovascular disease abnormalities in long-term survivors of Hodgkin and mediastinal non-Hodgkin lymphoma treated with mediastinal radiotherapy and/or anthracyclines compared with healthy control subjects?
Cardiovascular magnetic resonance identifies subclinical impairments in left ventricular ejection fraction, myocardial strain, LV mass, and native myocardial T1 in long-term lymphoma survivors at a mean of 20 years after mediastinal radiotherapy and anthracycline therapy.
Answers are grounded in this paper and cite their sources.
CMR may detect subclinical LV impairment in long-term lymphoma survivors; hypothesis-generating for native T1 in cardiotoxicity surveillance.
Long-term survivors of Hodgkin lymphoma (HL) and mediastinal non-Hodgkin lymphoma experience late adverse effects of radiotherapy and/or anthracycline-containing chemotherapy, leading to premature cardiovascular morbidity and mortality. The aim of this study was to identify markers for subclinical cardiovascular disease using cardiovascular magnetic resonance (CMR) in survivors of HL and non-Hodgkin lymphoma. CMR was performed in 80 lymphoma survivors treated with mediastinal radiotherapy with or without anthracyclines, and results were compared with those among 40 healthy control subjects matched for age and sex. Of the 80 lymphoma survivors, 98% had histories of HL, the mean age was 47 ± 11 years, and 54% were male. Median radiotherapy dose was 36 Gy (interquartile range: 36-40 Gy), and radiotherapy was combined with anthracyclines in 70 lymphoma survivors (88%). Mean time between diagnosis and CMR was 20 ± 8 years. Significantly lower left ventricular (LV) ejection fraction (53% ± 5% vs 60% ± 5%; P < 0.001) and LV mass (47 ± 10 g/m2 vs 56 ± 8 g/m2; P < 0.001) and higher LV end-systolic volume (37 ± 8 mL/m2 vs 33 ± 7 mL/m2; P = 0.013) were found in lymphoma survivors. LV global strain parameters were also significantly worse in lymphoma survivors (P < 0.02 for all). Native myocardial T1 was significantly higher in lymphoma survivors compared with healthy control subjects (980 ± 33 ms vs 964 ± 25 ms; P = 0.007), and late gadolinium enhancement was present in 11% of the survivors. Long-term lymphoma survivors have detectable changes in LV function and native myocardial T1 on CMR. Further longitudinal studies are needed to assess the implication of these changes in relation to treatment and clinical outcome.
No takes yet. Share an insight, caveat, or question.
Velde et al. (2021) conducted a cross-sectional in Subclinical cardiovascular disease in long-term survivors of Hodgkin and mediastinal non-Hodgkin lymphoma (n=120). Mediastinal radiotherapy (median 36 Gy) with or without anthracycline-containing chemotherapy evaluated by cardiovascular magnetic resonance (CMR) vs. Healthy control subjects matched for age and sex without cardiovascular disease was evaluated on Left ventricular ejection fraction (%) on cardiovascular magnetic resonance (p=<0.001). Long-term lymphoma survivors treated with mediastinal radiotherapy had lower LVEF and higher native myocardial T1 on CMR than controls.
Synapse has enriched 10 related papers. Consider them for comparative context: